等待開盤 11-18 09:30:00 美东时间
+0.075
+8.02%
今日重点评级关注:摩根大通:维持CytomX Therapeutics"超配"评级,目标价从11美元升至12美元;康托·菲茨杰拉德:维持Exodus Movement"超配"评级,目标价从15美元升至16美元
11-13 11:50
HC Wainwright & Co. analyst Matthew Keller maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and lowers the price target from $31 to $11.
11-13 01:21
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.39) by 25.64 percent. This is a 60.16 percent increase over losses of $(1.23) per share from the same period last year.
11-12 19:55
今日重点评级关注:花旗:上调如瑞迪博士"买入"评级,目标价从1040美元升至1450美元;加拿大帝国商业银行:维持Inventiva"买入"评级,目标价从20美元升至21美元
09-30 08:33
PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in the broader patient population for the treatment of acute CDI, has potential to ...
09-29 20:07
Acurx Pharmaceuticals (NASDAQ:ACXP) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis...
09-18 20:03
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 71.96 percent increase over losses of $(1.89) per share from the same period last year.
08-14 19:02
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the successful outcome of a Type C Meeting conducted with FDA on July 13, 2026 to discuss ibezapolstat's Phase 3 cli...
08-03 20:08
STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibi...
04-29 20:00
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
04-16 20:10